# Revelation Biosciences Inc. (REVB)

Source: https://www.quantisnow.com/company/REVB
Generated: 2026-11-10T08:53:28.066Z

- Ticker: REVB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001810560
- Website: https://www.revbiosciences.com

## About

Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.

## Latest REVB news and filings

- 2026-11-05 22:29 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-results-of-operations-6777474)
- 2026-11-05 22:29 UTC [Earnings] [Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026](https://www.quantisnow.com/insight/revelation-biosciences-inc-announces-financial-results-for-the-three-and-6777471)
- 2026-11-05 22:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-revelation-biosciences-inc-6777453)
- 2026-10-16 13:00 UTC [Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026](https://www.quantisnow.com/insight/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-6748825)
- 2026-08-19 21:07 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-leadership-update-financial-6688786)
- 2026-08-19 13:00 UTC [Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study](https://www.quantisnow.com/insight/revelation-biosciences-selects-avance-clinical-as-cro-for-phase-23-6687974)
- 2026-08-18 21:00 UTC [SEC Form 4] [Chief Financial Officer Zygmont Chester Stanley Iii was granted 208,073 shares, gifted 208,073 shares and received a gift of 208,073 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-zygmont-chester-stanley-iii-was-granted-208073-6687045)
- 2026-08-18 21:00 UTC [SEC Form 4] [Director Chawla Lakhmir S was granted 32,011 shares, increasing direct ownership by 263% to 44,169 units (SEC Form 4)](https://www.quantisnow.com/insight/director-chawla-lakhmir-s-was-granted-32011-shares-increasing-direct-6687040)
- 2026-08-18 21:00 UTC [SEC Form 4] [Director Roper Jess was granted 32,011 shares, increasing direct ownership by 250% to 44,839 units (SEC Form 4)](https://www.quantisnow.com/insight/director-roper-jess-was-granted-32011-shares-increasing-direct-ownership-6687037)
- 2026-08-18 21:00 UTC [SEC Form 4] [Chief Executive Officer Rolke James was granted 208,076 shares, increasing direct ownership by 97% to 422,814 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-rolke-james-was-granted-208076-shares-increasing-6687021)
- 2026-08-18 21:00 UTC [SEC Form 4] [Director Carver Jennifer was granted 32,011 shares, increasing direct ownership by 251% to 44,769 units (SEC Form 4)](https://www.quantisnow.com/insight/director-carver-jennifer-was-granted-32011-shares-increasing-direct-ownership-6687019)
- 2026-08-14 14:24 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-revelation-biosciences-inc-6682252)
- 2026-08-06 20:19 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-results-of-operations-6669381)
- 2026-08-06 20:15 UTC [Market Insight] [Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026](https://www.quantisnow.com/insight/revelation-biosciences-inc-announces-financial-results-for-the-three-and-6669204)
- 2026-08-06 20:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-revelation-biosciences-inc-6668946)
- 2026-08-03 13:00 UTC [Market Insight] [Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury](https://www.quantisnow.com/insight/independent-market-assessment-results-show-94-billion-total-addressable-market-6658999)
- 2026-07-21 20:05 UTC [Market Insight] [Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/revelation-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6643734)
- 2026-07-13 20:33 UTC [SEC Form 8-A12B filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-a12b-filed-by-revelation-biosciences-inc-6635548)
- 2026-07-13 20:05 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-entry-into-a-6635342)
- 2026-07-10 20:05 UTC [Market Insight] [Revelation Biosciences Announces Adoption of Stockholder Rights Plan](https://www.quantisnow.com/insight/revelation-biosciences-announces-adoption-of-stockholder-rights-plan-6634056)
- 2026-06-24 20:47 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-leadership-update-amendments-6614466)
- 2026-06-01 21:26 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-other-events-financial-6582440)
- 2026-06-01 13:00 UTC [Market Insight] [Revelation Biosciences Expands Acute Kidney Injury Advisory Board](https://www.quantisnow.com/insight/revelation-biosciences-expands-acute-kidney-injury-advisory-board-6580937)
- 2026-05-15 15:34 UTC [SEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-revelation-biosciences-inc-6556457)
- 2026-05-11 13:56 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-revelation-biosciences-inc-6544167)
- 2026-05-11 13:00 UTC [Market Insight] [Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders](https://www.quantisnow.com/insight/revelation-biosciences-inc-releases-corporate-update-letter-to-stockholders-6544038)
- 2026-05-07 20:23 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-results-of-operations-6539605)
- 2026-05-07 20:15 UTC [Market Insight] [Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026](https://www.quantisnow.com/insight/revelation-biosciences-inc-announces-financial-results-for-the-three-months-6539305)
- 2026-05-07 20:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-revelation-biosciences-inc-6539017)
- 2026-05-01 21:32 UTC [SEC Form 4] [Chief Executive Officer Rolke James covered exercise/tax liability with 10,115 shares, decreasing direct ownership by 4% to 214,738 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/chief-executive-officer-rolke-james-covered-exercisetax-liability-with-10115-6527518)
- 2026-05-01 21:31 UTC [SEC Form 4] [Chief Financial Officer Zygmont Chester Stanley Iii covered exercise/tax liability with 13,285 shares (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-financial-officer-zygmont-chester-stanley-iii-covered-exercisetax-liability-6527516)
- 2026-04-30 20:31 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-revelation-biosciences-inc-6524930)
- 2026-04-15 20:13 UTC [SEC Form S-8] [SEC Form S-8 filed by Revelation Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-revelation-biosciences-inc-6501266)
- 2026-04-06 13:00 UTC [Market Insight] [Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board](https://www.quantisnow.com/insight/revelation-biosciences-announces-formation-of-acute-kidney-injury-advisory-board-6488892)
- 2026-03-30 13:00 UTC [Market Insight] [Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study](https://www.quantisnow.com/insight/revelation-biosciences-inc-presents-additional-positive-data-from-prime-clinical-6476154)
- 2026-03-24 13:00 UTC [Market Insight] [REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference](https://www.quantisnow.com/insight/reminder-revelation-biosciences-to-host-fireside-chat-at-38th-annual-6466415)
- 2026-03-19 20:18 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-material-modification-to-6461646)
- 2026-03-19 13:00 UTC [Market Insight] [Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference](https://www.quantisnow.com/insight/revelation-biosciences-to-host-fireside-chat-at-38th-annual-roth-6460941)
- 2026-02-26 21:25 UTC [SEC Form 8-K] [Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/revelation-biosciences-inc-filed-sec-form-8-k-results-of-operations-6416502)
- 2026-02-26 21:15 UTC [Market Insight] [Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025](https://www.quantisnow.com/insight/revelation-biosciences-inc-announces-financial-results-for-the-three-and-6416194)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/REVB
- Earnings history: https://www.quantisnow.com/earnings/REVB
- Dividend history: https://www.quantisnow.com/dividends/REVB
- Insider transactions: https://www.quantisnow.com/insiders/REVB
- Options chain: https://www.quantisnow.com/options/REVB
- SEC 8-K filings only: https://www.quantisnow.com/company/REVB/8-k
- RSS and alerts for REVB: https://www.quantisnow.com/docs/rss-feeds.md